Insider Buying: Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Major Shareholder Buys 8,374 Shares of Stock

Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) major shareholder Perceptive Advisors Llc bought 8,374 shares of the firm's stock in a transaction dated Monday, April 1st. The shares were purchased at an average price of $3.25 per share, with a total value of $27,215.50. Following the acquisition, the insider now directly owns 8,601,960 shares in the company, valued at approximately $27,956,370. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.

Perceptive Advisors Llc also recently made the following trade(s):

• On Wednesday, April 3rd, Perceptive Advisors Llc bought 309,847 shares of Aldeyra Therapeutics stock. The stock was acquired at an average cost of $4.09 per share, for a total transaction of $1,267,274.23.

Aldeyra Therapeutics Price Performance

ALDX traded up $0.60 during trading hours on Wednesday, reaching $4.15. 2,309,872 shares of the stock traded hands, compared to its average volume of 534,890. Aldeyra Therapeutics, Inc has a fifty-two week low of $1.42 and a fifty-two week high of $11.97. The company has a market cap of $244.44 million, a price-to-earnings ratio of -6.48 and a beta of 1.51. The firm's fifty day simple moving average is $3.34 and its two-hundred day simple moving average is $3.42.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last announced its earnings results on Thursday, March 7th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.13. On average, research analysts predict that Aldeyra Therapeutics, Inc will post -0.26 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ALDX. JPMorgan Chase & Co. grew its stake in Aldeyra Therapeutics by 21.3% in the first quarter. JPMorgan Chase & Co. now owns 22,835 shares of the biotechnology company's stock worth $101,000 after purchasing an additional 4,012 shares in the last quarter. Raymond James & Associates grew its position in shares of Aldeyra Therapeutics by 21.2% in the 1st quarter. Raymond James & Associates now owns 26,306 shares of the biotechnology company's stock worth $117,000 after acquiring an additional 4,609 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Aldeyra Therapeutics by 12.2% in the 1st quarter. Bank of New York Mellon Corp now owns 209,815 shares of the biotechnology company's stock valued at $932,000 after acquiring an additional 22,748 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Aldeyra Therapeutics by 11.7% in the 1st quarter. Rhumbline Advisers now owns 47,596 shares of the biotechnology company's stock valued at $212,000 after acquiring an additional 4,996 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Aldeyra Therapeutics by 5.2% during the 1st quarter. Vanguard Group Inc. now owns 2,961,635 shares of the biotechnology company's stock valued at $13,165,000 after acquiring an additional 147,711 shares in the last quarter. 59.71% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ALDX has been the subject of a number of research reports. Oppenheimer raised shares of Aldeyra Therapeutics from a "market perform" rating to an "outperform" rating and set a $10.00 price target for the company in a research report on Wednesday. StockNews.com raised Aldeyra Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday, January 29th. Finally, HC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of Aldeyra Therapeutics in a report on Tuesday.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.